MARKET

VSTM

VSTM

Verastem
NASDAQ
7.76
+0.01
+0.13%
After Hours: 8.14 +0.38 +4.90% 19:55 12/19 EST
OPEN
7.76
PREV CLOSE
7.75
HIGH
8.07
LOW
7.59
VOLUME
5.57M
TURNOVER
--
52 WEEK HIGH
11.25
52 WEEK LOW
3.455
MARKET CAP
584.48M
P/E (TTM)
-1.9288
1D
5D
1M
3M
1Y
5Y
1D
Verastem streamlines leadership team amid strategic transition
TipRanks · 1d ago
Verastem Names John Johnson Chairman and Michael Kauffman President of Development
Reuters · 1d ago
Guggenheim Keeps Their Buy Rating on Verastem (VSTM)
TipRanks · 4d ago
Verastem Oncology announces management changes
Seeking Alpha · 5d ago
Verastem Names New Board Chair, Moves Michael Kauffman to Development Team
Dow Jones · 5d ago
Verastem Appoints John Johnson As Chairman Of The Board; Co. Announces That It Has Completed The Additional Patient Enrollment For Ramp 301, Its International Phase 3 Confirmatory Trial In Recurrent LGSOC
Benzinga · 5d ago
*Verastem Names Michael Kauffman President of Development
Dow Jones · 5d ago
*Verastem Names John Johnson Chairman
Dow Jones · 5d ago
More
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.

Webull offers Verastem Inc stock information, including NASDAQ: VSTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VSTM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VSTM stock methods without spending real money on the virtual paper trading platform.